U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H24N8O7S2
Molecular Weight 612.637
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CEFPIRAMIDE

SMILES

[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)C4=CN=C(C)C=C4O)C5=CC=C(O)C=C5)C(O)=O

InChI

InChIKey=PWAUCHMQEXVFJR-PMAPCBKXSA-N
InChI=1S/C25H24N8O7S2/c1-11-7-16(35)15(8-26-11)20(36)27-17(12-3-5-14(34)6-4-12)21(37)28-18-22(38)33-19(24(39)40)13(9-41-23(18)33)10-42-25-29-30-31-32(25)2/h3-8,17-18,23,34H,9-10H2,1-2H3,(H,26,35)(H,27,36)(H,28,37)(H,39,40)/t17-,18-,23-/m1/s1

HIDE SMILES / InChI

Molecular Formula C25H24N8O7S2
Molecular Weight 612.637
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Cefpiramide or SM-1652 (sodium 7-[D(-)-alpha-(4-hydroxy-6-methylpyridine-3-carboxamido)-alpha-(4-hydroxyphenyl)acetamido]-3-[(1-methyl-1H-tetrazol-5-yl) thiomethyl]-3-cephem-4-carboxylate) is a semisynthetic cephalosporin derivative with a broad spectrum of antibacterial activity. This antibiotic has been reported to have potent in vitro and in vivo antibacterial activities against gram-positive and -negative bacteria.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
CEFPIRAMIDE SODIUM

AUC

ValueDoseCo-administeredAnalytePopulation
672 mg × h/L
1 g single, intravenous
CEFPIRAMIDE plasma
Homo sapiens
1598 mg × h/L
1 g single, intravenous
CEFPIRAMIDE plasma
Homo sapiens
672 mg × h/L
1 g single, intravenous
CEFPIRAMIDE plasma
Homo sapiens
1300 mg × h/L
1 g single, intravenous
CEFPIRAMIDE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
5.3 h
1 g single, intravenous
CEFPIRAMIDE plasma
Homo sapiens
13.8 h
1 g single, intravenous
CEFPIRAMIDE plasma
Homo sapiens
5.3 h
1 g single, intravenous
CEFPIRAMIDE plasma
Homo sapiens
12 h
1 g single, intravenous
CEFPIRAMIDE plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
1.9%
1 g single, intravenous
CEFPIRAMIDE plasma
Homo sapiens
10.4%
1 g single, intravenous
CEFPIRAMIDE plasma
Homo sapiens

Doses

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as victim

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
1-2 gm daily in 2 divided doses by inj.
Route of Administration: Parenteral
In Vitro Use Guide
As judged by the MIC50 and the MIC90 values, cefpiramide was one of the most active cephalosporins against Pseudomonas aeruginosa (MIC50 2.9 micrograms/ml, MIC90 64 micrograms/ml), staphylococci (MIC50 1.2 micrograms/ml, MIC90 10 micrograms/ml) and Enterococcus faecalis (MIC50 13 micrograms/ml, MIC90 43 micrograms/ml). Cefpiramide had moderate activity against Enterobacteriaceae (MIC50 4 micrograms/ml, MIC90 108 micrograms/ml), comparable to that of the older second-generation cephalosporins.
Substance Class Chemical
Record UNII
P936YA152N
Record Status Validated (UNII)
Record Version